Table 2.

Frequency of CTCAE Grade 3/4 Hematological Toxicity (%) by Drug in Primary Brain Tumor Trials^a

	Neutropenia	Lymphopenia	Thrombocytopenia	Anemia	References
Temozolomide	7	7	12	1	Stupp et al.76
Procarbazine	3	Not specified	4	2	Yung et al.82
Lomustine	20	0	25	2.4	Wick et al.83
Vincristine	—	—	—	—	No single agent data, probably low risk
PCV	32	Not specified	21	7	van den Bent et al.84
Bevacizumab	0	0	0	0	Kreisl et al.85
	0	2.3	0	0	Odia et al.86
Vemurafenib	—	—	—	2	Larkin et al.148
Dabrafinib/tramatenib	10	—	—	—	Wen et al.87
Laroctrectinib (n = 33, including only 7 adults)	3	Not reported	Not reported	0	Doz et al.88
Entrectinib	—	—	—	—	No data

CTCAE, Common Terminology Criteria for Adverse Events.

^aSee dedicated chapters for management of these toxicities and reexposure to therapy.